https://www.selleckchem.com/pr....oducts/Temsirolimus.
7; 95 % CI 4.3-5.1]; Opioid+/ NAS- [aRR 3.7; 95 %CI 3.1-4.5]) and a year after birth (Opioid+/ NAS+ [aRR 3.7; 95 %CI 3.4-4.0]; Opioid+/ NAS- [aRR 2.8; 95 %CI 2.3-3.4]). Infants with maternal opioid exposure and/or NAS were more likely than Opioid-/NAS- infants to have ≥2 sick visits and any ED visits in the year after birth. Infants with NAS and/or maternal opioid exposure had greater healthcare utilization than infants without NAS or opioid exposure. Efforts to mitigate future hospitalization risk and encourage participation in pr
Like
Comment
Share
